Observational studyCancer immunology, immunotherapy : CII2026
Radiotherapy dose may not affect prognosis in ESCC patients receiving first-line chemoradiotherapy-immunotherapy: A multicenter retrospective study.
Observational study in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombined immunotherapy based on radiotherapy and chemotherapy is increasingly widely applied in clinical practice for patients with non-surgical treatment of esophageal cancer. However, radiotherapy doses in triple combination therapy have not received much attention. Therefore, a retrospective, non-interventional, real-world study of patients with esophageal squamous cell carcinoma (ESCC) was conducted. The primary objective was to assess whether radiotherapy dose is a determining factor in the prognosis of ESCC patients in a triple therapy.
methodsA total of 1283 ESCC patients receiving triple therapy were collected from 7 cancer centers in China between January 2019 and December 2022. Among them, 299 ESCC patients receiving the first-line triple therapy were eligible for enrollment. Due to different radiotherapy doses, patients were classified into a high-dose (HD) group at 60Gy and a low-dose (LD) group at 50.4Gy. Propensity Score Matching (PSM) analysis was conducted to compare and analyze differences in outcomes, toxicity, and failure patterns between the two groups. Further subgroup analysis was performed to identify the individual population.
resultsOf the 299 ESCC patients eligible for enrollment, 198 (66.2%) were in the HD group and 101 (33.8%) were in the LD group. After PSM, there were 93 patients in each group. The median follow-up time was 25.5 months (95CI: 18.6-32.4). The median overall survival (mOS) and median progression-free survival (mPFS) in the LD group were 31.3 months (95%CI: 16.5-46.2) and 17.0 months (95%CI: 15.1-19.0), respectively. The mOS and mPFS in the HD group were 28.5 months (95%CI: 16.1-40.9) and 20.6 months (95%CI: 13.5-27.8), respectively. There was no statistically significant difference between the HD group and the LD group (X
conclusionMulticenter data from China showed that higher radiotherapy doses provide no survival benefit for ESCC patients receiving first-line triple therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.